Health Populi
JUNE 24, 2021
While telehealth and virtual care stood up quickly in 2020, questions remain about how it will/can persist in terms of funding, regulation, and business models. We also expect innovation to come out of pharma and biotech labs, and who will pay for new-new therapies?
Health Populi
FEBRUARY 5, 2023
Whether looking at biotech beauty and what “clean” really means, effectively dealing with obesity, or biohacking our biology, wellness-engaged health citizens are not interesting in the shiny new thing without data backing up claims. Being Missourian in spirit and intent: seeking the science and the evidence.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Health Populi
JUNE 18, 2020
In today’s pharma/biotech market, the “specialty” label is given to many therapies: for products addressing rare diseases, risk-management, and above all, high cost drugs. The phrase “specialty drugs” originated in the 1970s in the advent of injectable and infusion therapies. Other countries outside of the U.S.
Health Populi
JULY 2, 2018
Health Populi’s Hot Points: Healthcare delivery is becoming more digital, via electronic health records, telehealth and virtual visits, remote health monitoring, and self-care tools. What was intriguing about that research is that biotech was much more trusted than pharma, with biotech being seen as more innovative.
Lloyd Price
FEBRUARY 23, 2025
physicians, facilitates professional networking, patient care coordination, telehealth, and access to medical updates, making it a vital tool for healthcare professionals. While giants like UnitedHealth or biotech stars like Vertex Pharmaceuticals often dominate headlines, Doximitys niche focus and execution have propelled it ahead.
Society for Participatory Medicine
FEBRUARY 1, 2023
This activity sent pharma and biotech companies scrambling to hire DE&I officers and related patient advocacy, engagement, and experience personnel as they came to terms with this foreign notion of actually collaborating with real, live patients. She is currently contracted by Parexel as their first Patient Ambassador.
Lloyd Price
MARCH 1, 2025
Outlook for 2025 Multiples are likely to hold steady at 4-6x revenue for most HealthTech firms, with upward pressure in AI, telehealth, and analytics if deal volume surges. Big Pharmas looming patent cliffs could drive outlier deals (7-8x or more) for late-stage innovators, especially in biotech-adjacent HealthTech.
Expert insights. Personalized for you.
270 
Let's personalize your content